A Study to Learn How Well the Drug Vericiguat Works and How Safe it is Under Real World Conditions in Indian Participants After Worsening of a Long-term Heart Condition in Which the Left Side of the Heart Does Not Pump Blood as Well as it Should (Chronic Heart Failure With Reduced Ejection Fraction)

Launched by BAYER · Dec 12, 2022

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female participants aged ≥18 years at the time point of signing ICF
• • Has a history of chronic HF (NYHA class II-IV) on standard therapy before qualifying HF decompensation
• • Has chronic HF with reduced LVEF (\<45%) after a WHF event (defined as HF hospitalization or use of iv diuretics for HF \[without hospitalization\])
• • Is capable of giving signed ICF and willing to comply with the study-related procedures
• * Female participants in the following categories:
• • A female who is not of reproductive potential, defined as a female who either: (a) is postmenopausal (defined as at least 12 months with no menses in women ≥45 years of age); (b) has had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy, or bilateral tubal ligation/occlusion at least 6 weeks prior to Screening; or (c) has a congenital or acquired condition that prevents childbearing
• • A female who is of reproductive potential and agrees to avoid becoming pregnant while receiving the study drug and for 14 days after the last dose of the study drug by complying with one of the following: (a) practice abstinence from heterosexual activity or (b) use (and have her partner use) acceptable, highly effective contraception methods during heterosexual activity.
• Exclusion Criteria:
• * Is clinically unstable at the time of screening defined by:
• • Administration of any iv treatment within 24 hours until start of study intervention, and/or
• • SBP \< 100 mmHg or symptomatic hypotension.
• • Has concurrent or anticipated use of PDE5 inhibitors, or a sGC stimulator such as riociguat.
• • Has known allergy or hypersensitivity to any sGC stimulator.
• • Has severe hepatic insufficiency such as with hepatic encephalopathy.
• • Has severe renal impairment with eGFR \< 15 mL/min/1.73m\*2 (calculated based on the MDRD equation) or on dialysis.
• • Is pregnant or breast feeding or plans to become pregnant or to breastfeed during the course of the trial.
• • Participated in another interventional clinical study and treatment with another investigational product ≤ 30 days prior to screening.